Blueprint Medicines Corporation Price, Consensus and EPS Surpriseīlueprint Medicines Corporation price-consensus-eps-surprise-chart | Blueprint Medicines Corporation Quote Zacks Rank and Other Stocks to Considerīlueprint Medicines currently carries a Zacks Rank #3 (Hold). The FDA had previously breakthrough therapy designation to Ayvakit for the treatment of moderate to severe indolent SM.īlueprint Medicine expects a decision from the FDA on May 22, 2023. In late January 2023, Blueprint Medicine announced that the FDA has accepted the company’s supplemental new drug application for Ayvakit (avapritinib) for the treatment of adults with indolent systemic mastocytosis (SM) under priority review. This guidance excludes revenues from the anticipated Ayvakit indication expansion in ISM in mid-2023.īlueprint Medicine also expects $40 million to $50 million in collaboration revenues from existing collaborations. The Zacks Consensus Estimate for the same currently stands at $199.94 million. Loss per share for the full year was $9.35 which was narrower than the Zacks Consensus Estimate of a loss of $9.41 per share.īlueprint Medicines expects to achieve in the range of $130-$140 million in Ayvakit net product revenues for advanced SM and GIST, rolling into 2023. Sales surpassed the Zacks Consensus Estimate of $198.5 million as well as the guided range of $180-$200 million. Revenues in the full-year 2022 were clocked at $204.04 million, portraying a 13.30% increase compared with 2021 results. Selling, general and administrative expenses were $64 million, up 18.52% year over year, on account of higher costs related to the commercialization of Ayvakit/Ayvakyt (the brand name of Ayvakit in Europe).īlueprint Medicines had cash, cash equivalents and investments worth $1078.5 million as of Dec 31, 2022, higher than $1,034.6 million in the year-ago quarter. In the year-ago quarter, research and development expenses included $260 million incurred through the acquisition of Lengo Therapeutics and stand as the primary driver for the decrease in expenses in the reported quarter. Research and development expenses were $1117.8 million, down 67% from the year-ago figure. The company suffered a year-over-year decline of 89.98% in collaboration revenues to $8.7 million. As a result, Blueprint Medicines’ current product revenues solely comprise sales from Ayvakit. The company only records the share of profit and loss for Gavreto in financial results and does not record any net product revenues from Gavreto sales. In July 2021, Blueprint Medicines transferred the responsibilities of booking the U.S. Blueprint Medicines is eligible to receive future milestone fees. In June 2018, the company inked a collaboration contract with CStone Pharmaceuticals to develop and commercialize its three clinical-stage candidates in Mainland China, Hong Kong, Macau and Taiwan, either as monotherapies or combo regimes. Sales of the drug grew slightly on a sequential basis and 50.1% on a year-over-year basis.Ĭollaboration revenues were $8.7 million, primarily generated from the agreements with CStone Pharmaceutical and Roche RHHBY. Net product revenues from Ayvakit sales were $30.1 million. Blueprint Medicines’ total revenues of $39 million comprised of net product revenues from Ayvakit (avapritinib) sales and collaboration revenues.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |